Revance Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody.
I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and I'm very pleased to be hosting Revance this afternoon at our virtual conference.
Joining us from the company, we have Mark Foley, President and CEO; Toby Schilke, CFO; and Jessica Serra from the IR team. Thanks so much for being with us. Really appreciate the time today.
Mark, I'll turn it over to you quickly for some opening remarks before we go into the Q&A.
Great. Thanks, Terence, appreciate the opportunity to be here at the conference today.
So maybe a couple of quick framing comments. After sort of 20 or so years of development, we're on the cusp of the approval of our neuromodulator. We recently announced that the FDA will be inspecting our facility before the end of June, and so we're obviously very anxious to get that product into the market initially in aesthetics. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |